FDA rejects MS drug
FDA has rejected alemtuzumab (Lemtrada, Genzyme, a Sanofi company) for the treatment of relapsing forms of multiple sclerosis. FDA has taken the position that Genzyme has not submitted evidence from...
View ArticleFDA drug approvals-November 2014
FDA actions in brief Hydrocodone bitartrate (Hysingla ER, Purdue Pharma), an extended-release (ER) opioid analgesic was approved to treat pain severe enough to require daily, around-the-clock,...
View ArticleNew drug approved by FDA for the treatment of relapsing MS
FDA has approved alemtuzumab (Lemtrada, Genzyme, A Sanofi Company) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Alemtuzumab is administered by intravenous infusion...
View ArticleDrugs in Perspective: Lemtrada (alemtuzumab)
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system and can lead to significant disability. An estimated 2.3 million people worldwide have been diagnosed with...
View Article
More Pages to Explore .....